The pharmaceutical industry is experiencing an unprecedented wave of merger and acquisition activity as companies scramble to address a looming $200 billion patent cliff by 2032. Industry experts now describe the situation as 'desperate', with the recent public bidding war between Pfizer and Novo Nordisk for Metsera serving as a prime example of how 'desperation is back' in Big Pharma. Some of the best-selling drugs in the world are facing loss of exclusivity in key jurisdictions, with estimates varying between $200 billion and $350 billion in total revenue at risk when factoring in smaller brands. This massive revenue threat has created what industry experts describe as a 'contact sport' environment for acquiring biotech assets, with M&A activity picking up dramatically in September and October 2025 following the clearing of policy overhangs from drug pricing concerns and tariff threats. According to healthcare market researcher analysis, approximately half of blockbuster drugs approved between 2014 and 2023 were acquired rather than developed internally, highlighting the critical role of acquisitions in pharmaceutical growth strategies. As one industry observer noted, 'the build vs. buy debate is dead' - when hundreds of billions in revenue are at risk, companies don't have time for slow internal R&D cycles.
At the 44th Annual J.P. Morgan Healthcare Conference, Pfizer CEO Albert Bourla announced a comprehensive pricing strategy alongside the company's decisive move beyond its Covid chapter. The pharmaceutical giant has implemented price increases on approximately 80 branded medications for 2026, with the most notable being a 15% rise for the COVID-19 vaccine Comirnaty. Most other adjustments remain below the 10% threshold, according to recent reports. Company leadership cites the need to counter inflation-driven cost increases as a primary reason for the adjustments, with the additional income earmarked to finance expansion in oncology and obesity treatment portfolios. This pricing strategy serves as a defensive measure to secure cash flow while Pfizer delivered three consecutive quarterly earnings beats on both revenue and profitability and simultaneously removed ₹46,760 crore ($5.6 billion) in operating expenses across 2024 and 2025.
The high-profile bidding war between Pfizer and Novo Nordisk over Metsera represents one of the most dramatic biotech M&A events of recent years, with Pfizer ultimately winning in a deal worth up to $10 billion. Industry experts note it's rare for bidding to take place in the public eye, with the competitive nature highlighting how companies are 'responding to what their situation is - they're about to have a lot of things come off patent.' The Metsera acquisition has significantly strengthened Pfizer's obesity portfolio, with Bourla noting early data from Metsera's amylin programs showing strong placebo-adjusted weight loss and favorable tolerability. The company plans to launch up to 10 Phase III trials in obesity through Metsera, including programs evaluating ultra-long-acting monthly GLP-1 and amylin-based therapies. This acquisition positions Pfizer in the increasingly competitive GLP-1 market, where more than 120 metabolic assets are currently in development across 60 companies, creating a deep pool of potential M&A targets. According to industry analysis, 'if you're a biotech founder with validated assets, you currently hold all the cards' in this environment.
According to Bloomberg TV interview and J.P. Morgan conference updates, Pfizer's acquired portfolio is performing exceptionally well, with CEO Albert Bourla stating the portfolio will generate approximately ₹83,500 crore ($10 billion) in sales this year with double-digit growth. The portfolio includes assets in obesity, oncology, and migraine treatments acquired through significant acquisitions including Seagen in oncology and Nurtec in migraine. Bourla emphasized that this double-digit growth will continue through 2025 and 2026, positioning the company for what he described as exponential growth that will be leading the industry after the 2028 patent expiration period. During the J.P. Morgan discussion, Bourla noted the company is in a better position now than over the previous two to three years, with upwards of ₹83,500 crore ($10 billion) in annual revenue from new products that are expected to continue offsetting losses from products facing exclusivity erosion.
According to both Bloomberg interview and J.P. Morgan conference details, Pfizer expects multiple significant clinical readouts in 2026, including two obesity portfolio studies in the first half of the year. Bourla outlined four key priorities for 2026: maximizing value from key transactions (Seagen, Biohaven, and Metsera), delivering critical R&D milestones, investing for 2028+ growth, and scaling artificial intelligence use across the organization. The company's IL-6 receptor fuel myeloma drug has a readout that if successful doubles the population they are targeting. Additional Phase III studies are expected across colorectal, endometrial, lung and bladder cancers, and chronic migraine prevention with Nurtec. Pfizer is also developing the first vaccine against Lyme disease, while the oncology portfolio currently absorbs approximately 40% of investments and will continue growing.
As reported by Bloomberg and reiterated at J.P. Morgan, Pfizer has invested almost ₹1,25,250 crore ($10 billion) of the earmarked ₹1,25,250-1,67,000 crore ($15 billion) for acquisitions, with ₹41,750-50,100 crore ($5-6 billion) remaining for future deals. The company is maintaining roughly ₹50,100 crore ($6 billion) in annual capacity for additional business development opportunities. Pfizer shares closed at $25.46, marking a modest year-to-date gain of 1.12%, with the stock attempting to establish support above the $25 level. The company offers a dividend yield of approximately 6.8% that remains attractive for income-focused portfolios, with Bourla reiterating Pfizer's commitment to maintaining its dividend. While buybacks are not currently a priority, the CEO emphasized the company is maintaining flexibility for the right opportunities to emerge, with the ₹41,750 crore ($500 million) reinvestment from cost savings continuing to go primarily into R&D to drive future growth. Industry analysts expect 2026 to provide one of the best investing opportunities in decades for biotech M&A, driven by cleared policy overhangs and additional rate cuts spurring more speculative investing. As one industry expert noted, '2026 isn't just a recovery; it's a gold rush' for biotech acquisitions.
